ArticleKidney international reports2025

DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 Trial.

Hiddo J L Heerspink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.